Corrixr Therapeutics, a pre-clinical genetic medicine company targeting lung, head & neck, and esophageal squamous cell carcinomas, today announced the appointment of Hilary M. Malone, Ph.D. as Chief Executive Officer. Dr. Malone brings more than 25 years of executive leadership experience across both multinational pharmaceutical companies and venture-backed biotech startups, combining deep expertise in science, regulatory strategy, clinical development, and patient/market access across the full drug development lifecycle. She is joining Corrixr at a pivotal moment as the company advances its lead program, CXR101, toward IND filing and first-in-human proof-of-mechanism trials.
